Canada - English - Health Canada

pro doc limitee - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

pro doc limitee - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

odan laboratories ltd - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents

Canada - English - Health Canada

odan laboratories ltd - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate,paracetamol -

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - codeine phosphate hemihydrate 9.75mg; doxylamine succinate 5mg;  ;  ; paracetamol 450mg;   - tablet - 9.75mg/5mg/450mg - active: codeine phosphate hemihydrate 9.75mg doxylamine succinate 5mg     paracetamol 450mg   - for patients over the age of 12 for the symptomatic relief of acute moderate to severe pain including headache, toothache, backache or pain associated with trauma or surgery. the calmative properties may be especially useful in the treatment of tension headache, migraine and period pain and the antipyretic properties may be useful in controlling fever. mersyndol is a suitable alternative for those individuals who cannot tolerate aspirin.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - metoprolol succinate 190mg equivalent to 77.69 mg free drug base;  ;   - modified release tablet - 190 mg - active: metoprolol succinate 190mg equivalent to 77.69 mg free drug base     excipient: colloidal silicon dioxide hypromellose macrogol 6000   magnesium stearate microcrystalline cellulose polyacrylate dispersion 30% povidone purified talc   sugar spheres titanium dioxide - hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. paediatric hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - metoprolol succinate 23.75mg equivalent to 9.71 mg free drug base;  ;   - modified release tablet - 23.75 mg - active: metoprolol succinate 23.75mg equivalent to 9.71 mg free drug base     excipient: colloidal silicon dioxide hypromellose macrogol 6000   magnesium stearate microcrystalline cellulose polyacrylate dispersion 30% povidone purified talc   sugar spheres titanium dioxide - hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. paediatric hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - metoprolol succinate 47.5mg equivalent to 19.42 mg free drug base;  ;   - modified release tablet - 47.5 mg - active: metoprolol succinate 47.5mg equivalent to 19.42 mg free drug base     excipient: colloidal silicon dioxide hypromellose macrogol 6000   magnesium stearate microcrystalline cellulose polyacrylate dispersion 30% povidone purified talc   sugar spheres titanium dioxide - hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. paediatric hypertension

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - metoprolol succinate 95mg equivalent to 38.84 mg free drug base;  ;   - modified release tablet - 95 mg - active: metoprolol succinate 95mg equivalent to 38.84 mg free drug base     excipient: colloidal silicon dioxide hypromellose macrogol 6000   magnesium stearate microcrystalline cellulose polyacrylate dispersion 30% povidone purified talc   sugar spheres titanium dioxide - hypertension. to reduce blood pressure and to reduce the risk of cardiovascular and coronary mortality (including sudden death), and morbidity. paediatric hypertension